Cargando…
多西他赛联合PD-1/PD-L1抑制剂二线治疗晚期非小细胞肺癌的临床分析
BACKGROUND AND OBJECTIVE: Programmed cell death 1 or programmed cell death ligand 1 inhibitor (PD-1/PD-L1 inhibitor) and docetaxel, as the standard second-line treatments of advanced non-small cell lung cancer (NSCLC) patients, have limited effects. There are few studies on whether docetaxel combine...
| Formato: | Online Artículo Texto |
|---|---|
| Lenguaje: | English |
| Publicado: |
中国肺癌杂志编辑部
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8503983/ https://www.ncbi.nlm.nih.gov/pubmed/34455735 http://dx.doi.org/10.3779/j.issn.1009-3419.2021.102.26 |